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Certain skin basement membrane components, such as bul-
lous pemphigoid antigens and epidermolysis bullosa acquis-
ita antigen, were discovered as a result of an autoimmune 
reaction. In this report, we describe a unique lamina lucida 
determinant associated with a novel immune-mediated sub-
epidermal bullous dermatosis. This unique bullous dermato-
sis resembled severe toxic epidermal necrolysis clinically. 
The histologic findings resemble dermatitis herpetiformis. 
Direct immunofluorescence microscopy detected linear im-
munoglobulin G (J gG) and C3 deposition at the cutaneous 
basement membrane zone of lesional and perilesional skin. 
Direct and indirect immunoelectron microscopy localized 
the IgG deposits to the lowest portion of the lamina lucida. 
T he patient's autoantibodies, belonging to the IgG t subclass, 
labeled basement membrane zone of normal intact human 
skin, oral mucosa, and conj unctiva, and localized to the der-
mal side of salt-split normal adult and neonatal human skin, 
Skin basement membrane zone (BMZ) is a complex struc-ture that serves as a interface barrier and as an adherent connection between the upper-layer epidermis and the lower-layer dermis. BMZ is composed of many different components. Some components were discovered because 
they were targets of an autoimmune reaction . Examples of sllch 
BMZ components include bullous pemphigoid (BP) antigen (A g) 
[1 - 3], epidermolysis bullosa acquisita (EBA) Ag [4], autoantigen for 
the bullous eruption of systemic lupus erythematoslls (BESLE) 
[5,6], and the autoantigen for linear IgA bullous dermatosis [7]. 
We now have the opportunity to identify a novel BMZ autoanti-
gen detected by the autoantibodies from a patient with a unique 
immune-mediated subepidermal blistering disease. This article 
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but failed to react with human fetal skin up to 142 gestational 
days. The patient's autoantibodies failed to react with bullous 
pemphigoid antigens or epidermolysis bullosa acquisita anti-
gen (type VII collagen) by immunoblotting. Instead, the pa-
tient's autoantibodies unequivocally labeled a 105-kilodalton 
(kD) protein in cellular extracts and conditioned media of 
human cultured keratinocytes and dermal fibroblasts . The 
titer of the patient's antibody against the cutaneous basement 
membrane zone and the intensity of the antibody reactivity 
against the 105-kD protein paralleled the patient's disease 
activity. Thus, this 105-kD lower lamina lucida protein rep-
resents a novel autoantigen and this patient's disease repre-
sents a deep lamina lucida pemphigoid, distinguishable from 
all other known autoimmune bullous dermatoses. Key 
words: autoantibody/basement membrane/ immunoblot/ 
immunoelectron microscopy. ] Invest Dermatol 101 :262-
267, 1993 
identifies and partially characterizes this novel autoantigen asso-
ciated with this unique disease. 
MATERIALS AND METHODS 
Case Report A 59-year-old man was admitted to the U niversiry of Mich-
igan Medical Center for a progressive bullous eruption covering 60% of his 
skin surface area. Examination upon admission revealed a few intact bullae, 
numerous large denuded areas, and extensive sloughing of skin. Lesional 
skin biopsy revealed a subepidermal blister with a predominantly neutrophi-
lic infiltration within the dermal papillae. Eosinophilic necrosis ofkeratino-
cyte was not observed. Direct immunofluorescence microscopy was per-
formed [8) on lesional and perilesional skin biopsy specimens. The patient 
responded well to treatments of prednisone and azathioprine and his lesions 
healed without scarring. 
Indirect Immuno6uorescence (IIF) Microscopy To assay for the 
presence of circulating IgG class anti-DMZ antibodies (Abs) in the patient's 
serum, !IF was performed [8) on the following tissue substrates: normal 
intact human skin, oral mucosa, and conjunctiva; salt-split normal human 
adult and neonatal skin; rat tongue epithelium; and mouse skin. To deter-
mine the IgG subclasses of the patient's autoantibody, !IF was performed on 
normal human skin using the patient'S serum, followed by fluorescein-con-
jugated monoclonal Abs against human IgG 1 , IgGz, IgGl , and IgG. (Sigma 
Chemical Company, St. Louis, MO) . To examine the ontogeny of this 
autoantigen, a panel of human fetal skin samples (with age range of54-142 , 
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gestational d) was employed. Sera from patients with EBA and. BP and 
normal individuals were used as positive and negative controls. Anti-type IV 
collagen Abs (Southern Biotechnology Assoc. Inc., Birmingham, AL) were 
used to confirm the level of separation in salt-split skin substrate. 
Immunoelectron Microscopy (IEM) Direct !EM was performed on a 
fresh ly frozen, perilesional skin biopsy specimen obtained from the patient 
as previously described [4,9]. Indirect !EM was performed with the patient's 
serum on normal human intact and salt-split skin substrates [4,9]. 
Preparation of Cellular Extracts Normal human keratinocytes and 
dermal fibroblasts were cultured as previously described [10,11]. Second-
passage cultured keratinocytes and seventh-passage cultured fibroblasts were 
extracted in a buffer contammg 65 mM Tns-HCI (Sigma), 10 mM sodium 
ethylenedinitrilotetraacetic acid (EDTA; EM Science, Cherry Hill, NJ), 20/0 
sodium dodecyl sul fate (SDS; Bio-Rad, Richmond, CAl, and 2 mM phenyl-
methylsulfonyl fluoride (PMSF; Sigma), pH 6.8 [8]. After pulse sonica.tion 
at 4°C for 1 min, the cell lysate was then centrifuged at 4 'C for 20 mm at 
15,000 X g, and the supernatant was collected. Human skin BMZ containing 
the 290-kD EBA Ag was extracted in 6 M GuHCl, Tris buffer, pH 9.0, 
1 mM EDTA, 1 mM PMSF; dialyzed against water; and resolubilized in 
125 mM Tris-HCI, 2% SDS, and 100 mM dithiothreitol (DTT; Sigma). 
Preparation of Culture Medium Soluble Proteins Serum-free kerati-
nocyte growth medium contains basal MCDB-153 medium [12] supple-
mented with bovine pituitary extract (70,ug/ml), epidermal growth factor 
(10 ng/ml), insulin (5 t-tg/ml), and hydrocortisone. (0.5 t-tg/ml). Condi-
tioned medium from confluent cultured human keratmocytes was collected 
after 48-h incubation. The medium was filtered (0.22 microns) and then 
concentrated by sequential 2-h centrifugations at 5000 RPM in 4 'C, using 
concentrators (W.R. Grace & Company, Beverly, MA) with pore sizes of 
10 kD and 30 kD. Culture medium of human dermal fibroblasts grown in 
serum-free Dulbecco's modified eagle medium (DMEM; GIBCO-BRL, 
Grand Island, NY) was collected after 6-h incubation for concentration. 
Im.munoblot Analyses SDS-polyacrylamide gel electrophoreses (SDS-
PAGE) (7.50/0 and 5%) were performed under reduced conditions [13] and 
the separated proteins were electrophoretically transblotted to nitrocellulose 
paper (Bio-Rad). Immunoblot analyses were p.reformed as preVIOusly dc-
scribed [8]. Control sera were from seven patients With proved BP, twO 
patients with proved EBA, nine patients with cicatricial pemphigoid (CP), 
and four normal individuals. The immunoblots werc reactcd with either a 
standardized substrate (3,3', 5,5'-tetramethyl-benzidine; Kirkeggard and 
Perry Laboratories, Gaithersburg, MD) or 0.1 % diaminobcnzidine (Sigma) 
in 10 mM citrate buffer (pH 5.2) and 0.90/0 hydrogen peroxide. 
RESULTS 
Direct Immunofluorescence Microscopy Direct immunoflu-
orescence microscopy performed on lesional and perilesional skin 
biopsy specimens revealed linear deposition of IgG (Fig 1) and C3 
along the skin BMZ. In areas of epidermal-dermal separation, these 
in vivo-bound immune reactants were localized exclusively to the 
dermal side of the clefts. 
Indirect Immunofluorescence Microscopy IIF performed on 
various epithelial tissues from different animal species revealed that 
IgG anti-BMZ Abs from our patient's serum, as well as IgG Abs 
from BP and EBA control sera, labeled the BMZ in normal intact 
human skin, oral mucosa, and conjunctiva. Our patient's anti-BMZ 
Abs, belonging to the IgG I subclass, bound exclusively to the der-
mal side (Fig 2) of the salt-split normal adult and neonatal human 
skin, similar to that observed with EBA or BESLE autoantibodies, 
but distinct from that observed with BP serum. Some species re-
striction of the autoantigen was observed by our patient's serum. 
Whereas BP and EBA sera labeled the BMZ of rat tongue epithe-
lium and mouse skin, our patient's serum did not. Surprisingly:, our 
patient's serum failed to react by IIF With the BMZ of fetal sk1l1 up 
to 142 d gestation, indicating that this BMZ constituent compo-
nent develops much later in fetal life than most BMZ components 
(Table I). 
Immunoelectron Microscopy Direct IEM on our patient's per-
ilesional skin biopsy specimen detected the IgG deposits at the low-
est portion of the lamina lucida (Fig 3A). Indirect IEM on intact 
normal human skin also localized the ill vitro binding sites of our 
patient's anti-BMZ Abs to the lowest portion of the lamina lucid a 
(Fig 3B). Indirect IEM on salt-split normal human skin confirmed 
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Figure 1. Direct immunofluorescence microscopy on the patient's peri le-
slOnal skm. A cryOsectlOn of skin was reacted with f1uorescein-cor~ugated 
goat antl-humall IgG and visualized with epifluorescence microscopy. Bar, 
133 t-tm. 
the lower lamina lucida binding by our patient's anti-BMZ Abs 
(illustration not shown). 
Immunoblot Analyses Because keratinocytes and dermal fibro-
blasts. are the most likely sources for the BMZ components, we 
exam1l1ed cultured human keratinocytes and dermal fibroblasts for 
synthesis of this new lamina lucida component. Our patient's serum 
reacted With Western blots of cellular extracts of keratinocytes and 
fibroblasts, identifying a 10S-kD Ag (lall es 1 alld 2, Fig 4). To differ-
entiate the involved autoantigen of the presenting case from those 
of currently known autoimmune subepidermal bullous dermatoses, 
the identical Western blots of both keratinocyte and fibroblast anti-
gens were reacted with BP sera and serum from normal individuals 
(Fig 4). BP control serum identified the 230-kD BP Ag in the 
Figure 2. Indirect immunofluorescence microscopy on cryosections of l M 
salt-split normal human skin substrates. The substrates were first reacted 
with the patient's serum (A), a bullous pemphigoid control serum (B) , oran 
epidermolysis bullosa aequisita control seru m (C), followed by reaction 
with fluorescein-conjugated goat anti-human IgG. Opell arrows, epidermal 
side of spl it; solid arrows, dermal side of split. Bar, 50 pm (A,B,C). 
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Table I. Ontogeny of Human Skin BMZ Antigens 
Gestational Age (weeks) 
Antigen' 6 8 10 12 16 >20 
Laminin X 
Type IV collagen X 
LDA-1 [35] X 
C6S [35] X 
HSPG [37] X 
EBAAg X 
Type VII co llagen X 
BPAg X 
19-DEJ-l [32] X 
KF-1 [35] X 
AF-l and AF-2 [35] X 
105-kD Agb X 
• C6S, chondroitin 6 sulfate proteoglycan; HSPG, heparan sulfate proteoglycan . 
• The Ag characterized by the current article. 
keratinocyte extracts but not in the fibroblast extracts. Normal con-
trol serum failed to react with any specific Ag. 
To determine whether our patient's serum reacts with the EBA 
Ag (type VII collagen), Western blots of human skin crude BMZ 
extracts containing the 290-kD EBA Ag [4] were reacted with the 
sera from our patient, a patient with EBA, and a normal individual. 
Whereas EBA control serum identified the 290-kD EBA Ag, the 
serum from our patient and a normal individual failed to react with 
this Ag (illustration not shown). 
We next examined whether this 105-kD Ag, synthesized by ker-
atinocytes and fibroblasts, was also secreted by these cells. Our pa-
tient's serum detected this 105-kD Ag in the Western blots of 
concentrated culture media of keratinocytes and fibroblasts (lan es 2 
and 5, Fig 5). The presence of this Ag in both the cellular extracts 
(lan es 1 al1d 4, Fig 5) and the culture media suggests that it is synthe-
sized and secreted by both keratinocytes and fibroblasts. 
To determine whether the titer of our patient's autoantibodies 
correlated with his disease activity, IIF and Western blots were 
performed with the patient's sera obtained during different disease 
stages (Fig 6). The IIF titer of the anti-BMZ Abs and the intensity of 
the serum reaction to the 105-kD Ag paralleled the patient's disease 
activity, further supporting the likelihood that this 105-kD Ag is 
the involved BMZ autoantigen. 
DISCUSSION 
Although the differential diagnosis of the presenting case would 
include BP, CP, EBA, and BESLE, this unique case represents a deep 
lamina lucida "pemphigoid-like" bullous dermatosis that is distinct 
from all other known autoimmune bullous dermatoses (Table II). 
Clinically, our case was characterized by the sudden onset of 
extensive bullae and sloughing of skin, initially resembling toxic 
epidermal necrolysis. Our case differs from EBA in that the latter is 
usually associated with milia and scarring [4]. It is different from BP 
in that BP tends to involve intertriginous areas and usually lacks 
clinically significant involvement within the oral cavity [14] . Fur-
thermore, it is distinguished from CP, which scars and predomi-
nantly affects mucous membranes [14]. In addition, it does not fit 
the diagnosis of BESLE, because our patient does not fulfill any of 
the American Rheumatism Association's criteria for the diagnosis of 
SLE [15]. 
Histopathologically, our case differs from many of the other 
IgG-associated subepidermal bullous dermatoses by the presence of 
a neutrophilic papillary dermal infiltrate, resembling dermatitis 
herpetiformis, a disease associated with granular IgA deposition at 
the papillary dermis [14]. 
Whereas the linear deposition of IgG is a common feature for 
EBA, BESLE, BP, and CP [1 -6,14], IlF on salt-split skin usually 
distinguishes them [16,17] . Whereas the circulating IgG Abs in 
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Figure 3. (A) Direct immunoelcctron mjcroscopy. The patient'S pcrile-
sional skin section was directly reacted with peroxidase-conjugated goat 
anti-human IgG . (B) Indirect immunoelectron microscopy. A normal 
human skin section was first reacted w ith the patient'S serum, followed by 
indirect visualization with peroxidase-conjugated goat anti-human IgG. 
Solid arrows, reaction products (black); open arrows, lamina densa (dark gray); 
E, epidermis; D, dermis. Bar, 1.2).1m (A ,B) . 
patients with EBA and BESLE bind to the dermal side of the salt-
split skin [4,5], the IgG Abs in patients with BP bind to the epider-
mal side [16,17]. Although it is controversial regarding their bind-
ing location, IgG Abs in most patients with CP reacted with the 
epidermal side or to both the epidermal and dermal sides [8 ,18]. The 
IgG Abs in our case reacted with the dermal side of salt-split skin, 
resembling the pattern of EBA and BESLE [4,5] . 
Applying the technique of indirect IEM, our case may be further 
distinguished from EBA, BESLE, and BP (Table II). Indirect IEM 
localizes the irl vitro binding sites ofBP autoantibodies to the hemi- \ 
desmosomes of basal keratinocytes [19,20]. By contrast, autoanti-
bodies from patients with EBA and BESLE bind to the lamina dens. 
and/or sub-lamina densa zone [4,5,9]. CP patients rarely have cir-
culating anti-BMZ Abs, thus their ill vitro binding sites have not 
been definitively delineated [21]. By direct IEM, most investigators 
noted ill vivo-bound immune deposits in CP to be localized within 
the lamina lucida [21]. However, because there is evidence suggest-
ing that itl vivo bound immune deposits as detected by direct !EM 
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Figure 4. W estern blots of human cultured keratinocyte extracts (lan es 1, 3, 
arid 5) and fibroblasts extracts (lan es 2, 4, and 6) were reacted with the 
patient's serum (PT), a bullous pemphigoid control serum (DP), or a normal 
serum (N), followed by visualization with peroxidase-conjugated goat anti-
human IgG. MW, molecular weight markers. Arrowhead, 230 kD; arrow, 
105 kD. 
may not represent the true ill vitro binding sites of Abs, the accurate 
ill vitro binding sites of CP autoantibodies remain unclear. It can be 
safely concluded, however, that in our patient, the in vitro binding 
sites of the ~nti-B~Z Abs ~ere loc~lized at the l~west portion of the 
lamina IUClda. ThiS localtzatton IS clearly dlSt111Ct from that ob-
served in BP, EBA, or BESLE. 
Because immunoblot analysis can identify both source(s) and mo-
lecular weight(s) (MW[sJ) of the involved autoantigen, it is there-
fore a definitive method for distinguishing autoimmune bullous 
dermatoses that are characterized by circulating anti-BMZ Abs 
(Table II) . Immunoprecipitation is another such method, but our 
patient's antibodies failed to precipitate any metabolically radiola-
beled specific keratinocyte Ag (Yancey KB, unpublished observa-
tion). Whereas sera from patients with EBA and BESLE identify 
BMZ Ags of290-kD and 145-kD, corresponding to domains on the 
1 2 3 4 5 
105 kD--7 (-105 kD 
KE KM KGM KE FM 
Figure 5. Western blots of human keratinocyte cellular extracts (KE; lalles 
1 and 4), concentrated culture media of keratinocytes (K.M; lane 2) and 
fibroblasts (FM; lane 5) , and concentrated keratinocyte growth medium 
alone (KGM; lane 3) were reacted with our patient's serum, followed by 
visualization with peroxidase-conjugated goat anti-human IgG. 
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Figure 6. W estern blots ofkeratinocyte cellular extracts were reacted with 
same dilution (1 : 100) of our patient's serum obtained from three different 
dates. The intensities of the serum reaction to the 10S-kD protein were 
correlated with the patient's disease activities and the titers of the patient's 
anti-DMZ antibodies. 
amino terminus of type VII collagen [4- 6,22,23], sera from patients 
with BP identify epidermal Ags of230 kD and 180 kD [1-3,24]' 
but not dermal Ags [1]. As for the autoantigens of CP, it has been 
repo~ted that t~ey a~e similar to BP Ags [2,8 ,25,26]. The autoanti-
gen 111 our patient IS a 105-kD Ag present in keratinocytes and 
fibroblasts. Therefore, its molecular size distinguishes it from EBA, 
BESLE, BP, or CP autoantigens. In addition, th e species restriction 
of this 105-kD Ag to primate epithelial BMZ is distinct from the 
non-rest~icted n~tur~ of the EBA and BP Ags. Recently, a new BMZ 
Ag assoCiated with l111ear IgA bullous dermatosis has been identified 
(7]'.T?is autoantigen associated with linear IgA bullous dermatosis 
IS dl~t111Ct f~om our 1.05-.kD Ag by its MW of97 kD and by its upper 
lam111a IUCIda localtzation [7] . More recently, epiligrin, a major 
human ke.ratinocyte int.egrin ligand, has been shown to be a target 
of an aut0111;mune reaction 111 a mu.cosal-predominant subepidermal 
bhstenng disease [27]. T hese patients possess autoantibodies that 
reacted with the dermal side of salt-split skin substrate and immu-
noprecipi.tated polypeptides of 170,145,1 25, and 95 kD (but not 
105 kD) 111 ~uman kerat1110cyte culture media [27]. Although these 
autoanttbodies [27] reacted to approximately the same location in 
t~e lower la.mina lucida (Figs 2 and 3) , these patients [27] manifested 
dtlferent citlllcal presentation and their Abs did not react with a 
105-kD protein. The MW of this 105-kD Ag is also distinct from 
other known components of the lamina lucida not associated with 
autoimmunity. LaH?inin, a ubiquitous lamina lucida glycoprotein, 
has two MW speCies, 220 and 440 kD [28]. Nicein , previously 
named BM 600 and identified by monoclonal Abs GB3, is a 600-kD 
I ~mina ~ucida glycoprotein consisting of three disulfide-linked pep-
tides with MWs of 93.5, 125, and 150 kDs [29]. AA3 is a 37-kD 
lamina lucida protein [30] . Epiligrin, a new lamina lucida glycopro-
tein, consists of three subunits, 170, 145 , and 135 kDs [31] . AI-
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Table II. Differentiation Between the Presenting Case and the Known Autoimmune Subepidermal Bul lous Dermatoses 
C haracterized by In Vivo Bound and Circulating Anti-BMZ IgGa 
O ur Patient EBA (4 ,9,16 ,17,23] BP (1 -3,14,16-20,24] CP (2,8,14,16- 18,21,25 ,26] 
Location of les ions General Extensors General (intertri ginous) Mucosae 
Sca rring N o Yes N o Yes 
IgG subclass IgG , IgG'_4 IgG ' _4 ? 
I1F (anti-BMZ on salt-sp lit skin) D ermis Dermis Epidermis Epidermis/ dermis/combined 
III Ililro binding sites of Abs Lowermost LL LD and/or sub-LD zone H emidesmosome ? 
Biochemical detection (Ag source) 
Kerati nocytes 105 kD 290/145 kDs 230/ 180 kDs 230/180/120 kDs 
Fibroblasts 105 kD 290/ 145 kDs No No 
BMZ extracts (dermal) N o 290/145 kDs No 
Type VII co llage n No + 
• LD, lamina densa; LL, lamina lucida. 
though epiligrin originall y was not discovered as an autoantigen, it 
has now been shown to be a target of an au toimmune reaction [27J. 
Another lamina lucida protein, 19-DEJ-1, is distinct from this 105-
kD Ag by its upper lamina lucida localization and by its MW of 
165 kD [32].~ In addition, th is 105-kD Ag is distinct from another 
upper lamina lucida - located anchoring filament protein named ka-
linin in MW and in localization [33J . Kalinin consists of three 
disulfide- linked non-identical chains of 165 kD, 155 kD, and 
140 kD . T he 155-kD chain, however, is proteolytically cleaved to 
105 kD [33]' wh ich is identical in MW to our autoantigen. Our 
autoantigen, therefore, may represent one of three chains ofkalinin. 
Although a 1 05-kD chain has not been identified in either nicein or 
epi li grin , recent biochemica l characterization of these three 
proteins - kalirlin, nicein, and epiligrin - revealed remarkable 
structural and biologic similarities [34] . It is suggested that these 
three prot'eins coul d be identical or closely related [27,34]. O ur 
105-kD autoantigen, therefore, could potentially represent one of 
the chains of nicein or epiligrin. However, our patient'S serum 
failed to immunoprecipitate any specific keratinocyte Ag, making 
our 105-kD protein an un likely candidate for epiligrin. Because 
antigen ic epitopes could reside at different locations as these pro-
teins span the lamina lucida, the differential localization of our 
autoantigen revealed by lEM does not completely exclude the possi-
bility of kalinin, nicein, or epiligrin . 
The ultrastructural localization of this 105-kD lamina lucida Ag 
is distinct from other known BMZ Ags localized within and below 
lamina densa such as KF-1, LDA-1, AF-1 , AF-2, entactin/nidogen, 
type IV, V, and VII collagens, hepara n sulfate proteoglycan, and 
chondroitin 6-sulfate proteoglycan [35 ,36]. 
Ontogenetica lly, most currently known BMZ Ags are detectable 
before 16 weeks gestational age [1 ,32,35,37,38] (Table I) .~,** This 
105-kD lamina lucida Ag, as well as two other sub-LD Ags AF- l 
and AF-2, are undetectable through at least 20 weeks gestational 
age, suggesting that this 1 05-kD Ag may not serve a critical role in 
the maintenance of dermal-epidermal integrity during early fetal 
life. Alternatively, the delayed expression of our autoantigen may 
re fl ect differe ntial epitope mapping . 
The discovery of the new skin BMZ Ag adds to the complexity of 
the basement membrane structure. Further investigations such as 
biochemical purification of the Ag and molecular cloning of the 
responsible gene will lead to the true identity of the Ag and may be 
contributory to the understanding of this Ag's role as a structural 
component of skin basement membrane. 
~ Fine J -D, Bynum K, Brysk M : LDA- l and 19-DE]-1 antigens: further 
characterization of two novel skin basement membrane components (abstr) . 
J In vest Dermatol 96 :536A, 1991. 
•• Horiguch i Y, Fine J -D, Couchman JR, Engva ll E: Express io n ofhepa-
ran su lfate proteoglycan and lami nin in developing human fetal sk in base-
ment membrane: differences ill ultrastructural localizatio n are dependent o n 
developmenta l age (abs tr). J Invest Dcrmatol 94:536A, 1990 . 
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ANNOUNCEMENT 
The International Melanoma Conference, Meial1oma- The Way Forward. will be held at the 
Sheraton Brisbane Hotel, Queensland, Australia 6-9 April 1994. The conference will review 
the most important areas of advancing knowledge in melanoma biology, genetics, etiology, 
clinical care, and prevention. Recommendations for high-priori ty activities over the next 5 -10 
years in respect to research, development, and implementation at both clinical and population 
levels will be formulated. For further information and/or a copy of the abstract guidelines for 
proffered papers or posters please write to International Melanoma Conference, P.O. Box 1280 
Milton, Queensland, 4064, Australia, Telephone: +6173690477. Facsimile: +617 3691512. 
Please note the deadline for receipt of abstracts in camera-ready format is 1 December 1993. 
